MC1R and neoplasm: When adjusting for different patient, tumor, and treatment‐related factors, HR for PFS and OS remained < 0.75 in favor of the MC1R‐R‐carriers, except when adjusting for factors associated with the primary melanoma; the survival advantage did not persist (Table 1).